03 September 2010
Keywords: Bayer, Xarelto, Visanne, VTE, Endometriosis, FDA, Europe, USA
Article | 7 December 2009
German drug major Bayer announced over the weekend details of data from the EINSTEIN Extension study for Xarelto (rivaroxaban), under development with US health care giant Johnson & Johnson, due to be presented at the American Society of Hematology in New Orleans conference on December 8.
There is limited new information on the EINSTEN study versus that previously seen in the abstract but there is an update on the US Food and Drug Administration regulatory status. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscriptions are £60 per month, pay as you go.
Find out more details.